Oncotarget

Reviews:

Contrast agents in dynamic contrast-enhanced magnetic resonance imaging

Yuling Yan _, Xilin Sun and Baozhong Shen

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:43491-43505. https://doi.org/10.18632/oncotarget.16482

Metrics: PDF 1590 views  |   HTML 2742 views  |   ?  


Abstract

Yuling Yan1,2, Xilin Sun1,2,3 and Baozhong Shen1,2

1 Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin, Heilongjiang, China

2 TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China

3 Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, California, USA

Correspondence to:

Baozhong Shen, email:

Xilin Sun, email:

Keywords: DCE-MRI, contrast agent, macromolecular contrast agent, nanoparticle, low molecular contrast agent

Received: January 07, 2017 Accepted: March 15, 2017 Published: March 22, 2017

Abstract

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a noninvasive method to assess angiogenesis, which is widely used in clinical applications including diagnosis, monitoring therapy response and prognosis estimation in cancer patients. Contrast agents play a crucial role in DCE-MRI and should be carefully selected in order to improve accuracy in DCE-MRI examination. Over the past decades, there was much progress in the development of optimal contrast agents in DCE-MRI. In this review, we describe the recent research advances in this field and discuss properties of contrast agents, as well as their advantages and disadvantages. Finally, we discuss the research perspectives for improving this promising imaging method.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16482